PALO ALTO, Calif., September 2, 2026
BridgeBio Pharma, Inc. announced plans to present new clinical data on the impact of investigational oral infigratinib on medical complications associated with achondroplasia at the Annual European Society for Paediatric Endocrinology (ESPE) Meeting 2026, taking place September 8–10 in Marseille, France. The company will feature a late-breaking oral presentation from the PROPEL 3 randomized controlled trial, alongside two posters and an ePoster covering longer-term efficacy and safety, development in children under three years of age, and the functional and medical impacts of hypochondroplasia. The presentations reflect BridgeBio’s efforts to evaluate whether targeting the underlying FGFR3 signaling pathway can address broader health consequences of skeletal dysplasia beyond disproportionate short stature.
PROPEL 3 to Highlight Medical Complications
The late-breaking oral presentation, titled “A Randomized Controlled Trial of Oral Infigratinib in Children with Achondroplasia: Results from the PROPEL 3 Study,” will be presented by Julie Hoover-Fong, M.D., Ph.D., of Johns Hopkins University, on September 9. Additional data will include longer-term efficacy and safety results for infigratinib in children with achondroplasia, presented by Melita Irving, M.D., of Guy’s and St Thomas’ NHS Foundation Trust. BridgeBio will also provide an update on PROPEL Infant and Toddler, an ongoing Phase 2/2b study evaluating oral infigratinib in children under three years old with achondroplasia. The program is designed to investigate treatment earlier in development, when children have significant growth potential and may be vulnerable to complications associated with abnormal skeletal development.
Targeting FGFR3 Signaling in Skeletal Dysplasia
Achondroplasia is the most common cause of disproportionate short stature and affects approximately 55,000 people in the U.S. and European Union, including up to 10,000 children and adolescents with open growth plates. The condition is caused by an activating variant in the FGFR3 gene, resulting in excessive FGFR3 signaling and disrupted growth plate development. Beyond short stature, achondroplasia can contribute to serious medical complications such as obstructive sleep apnea, middle ear dysfunction, kyphosis and spinal stenosis, potentially affecting long-term health and quality of life. Oral infigratinib is an investigational small-molecule FGFR3 inhibitor designed to reduce excessive FGFR3 activity and restore signaling toward levels that may support more normal bone growth.
Advertisement
Expanding Clinical Development Across Skeletal Dysplasias
BridgeBio is also using the ESPE meeting to highlight qualitative research examining medical challenges and functional impacts of hypochondroplasia, another skeletal dysplasia associated with altered FGFR3 signaling. The company’s presentations underscore a development strategy focused not only on increasing linear growth but also on understanding potential effects on medical complications and functional outcomes experienced by patients and families. The ongoing PROPEL clinical program is therefore evaluating oral infigratinib across different pediatric age groups while collecting longer-term safety and efficacy information. As new PROPEL 3 findings are presented, the data could provide additional insight into whether pharmacologic modulation of FGFR3 can deliver broader clinical benefits for children living with achondroplasia.
Source: BridgeBio Pharma, press relese
